Article
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma
2025-09-20
Abstract excerpt
Diffuse large B-cell lymphoma (DLBCL) remains a challenging disease with limited therapeutic options beyond standard immunochemotherapy. ETS transcription factors, including SPIB and SPI1, are implicated in lymphoma pathogenesis and can be targeted by the small molecule TK216, which disrupts ETS-DHX9 interactions. To explore mechanisms of resistance, we generated stable TK216-resistant clones from the ABC-DLBCL li...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1b2a3bfd-b784-5654-9169-514703d53164
- DOI
- 10.1101/2025.09.18.675797
